1 Introduction to Research & Analysis Reports
1.1 Gene-based Advanced Therapy Medicinal Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene-based Advanced Therapy Medicinal Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene-based Advanced Therapy Medicinal Overall Market Size
2.1 Global Gene-based Advanced Therapy Medicinal Market Size: 2022 VS 2029
2.2 Global Gene-based Advanced Therapy Medicinal Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene-based Advanced Therapy Medicinal Players in Global Market
3.2 Top Global Gene-based Advanced Therapy Medicinal Companies Ranked by Revenue
3.3 Global Gene-based Advanced Therapy Medicinal Revenue by Companies
3.4 Top 3 and Top 5 Gene-based Advanced Therapy Medicinal Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene-based Advanced Therapy Medicinal Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene-based Advanced Therapy Medicinal Players in Global Market
3.6.1 List of Global Tier 1 Gene-based Advanced Therapy Medicinal Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene-based Advanced Therapy Medicinal Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Gene-based Advanced Therapy Medicinal Market Size Markets, 2022 & 2029
4.1.2 Viral Gene Delivery System
4.1.3 Non-viral Gene Delivery System
4.2 By Type – Global Gene-based Advanced Therapy Medicinal Revenue & Forecasts
4.2.1 By Type – Global Gene-based Advanced Therapy Medicinal Revenue, 2018-2023
4.2.2 By Type – Global Gene-based Advanced Therapy Medicinal Revenue, 2024-2029
4.2.3 By Type – Global Gene-based Advanced Therapy Medicinal Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Gene-based Advanced Therapy Medicinal Market Size, 2022 & 2029
5.1.2 Neurological Diseases
5.1.3 Cancer
5.1.4 Other
5.2 By Application – Global Gene-based Advanced Therapy Medicinal Revenue & Forecasts
5.2.1 By Application – Global Gene-based Advanced Therapy Medicinal Revenue, 2018-2023
5.2.2 By Application – Global Gene-based Advanced Therapy Medicinal Revenue, 2024-2029
5.2.3 By Application – Global Gene-based Advanced Therapy Medicinal Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Gene-based Advanced Therapy Medicinal Market Size, 2022 & 2029
6.2 By Region – Global Gene-based Advanced Therapy Medicinal Revenue & Forecasts
6.2.1 By Region – Global Gene-based Advanced Therapy Medicinal Revenue, 2018-2023
6.2.2 By Region – Global Gene-based Advanced Therapy Medicinal Revenue, 2024-2029
6.2.3 By Region – Global Gene-based Advanced Therapy Medicinal Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Gene-based Advanced Therapy Medicinal Revenue, 2018-2029
6.3.2 US Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.3.3 Canada Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.3.4 Mexico Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Gene-based Advanced Therapy Medicinal Revenue, 2018-2029
6.4.2 Germany Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.3 France Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.4 U.K. Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.5 Italy Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.6 Russia Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.7 Nordic Countries Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.4.8 Benelux Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Gene-based Advanced Therapy Medicinal Revenue, 2018-2029
6.5.2 China Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.5.3 Japan Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.5.4 South Korea Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.5.5 Southeast Asia Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.5.6 India Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Gene-based Advanced Therapy Medicinal Revenue, 2018-2029
6.6.2 Brazil Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.6.3 Argentina Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Gene-based Advanced Therapy Medicinal Revenue, 2018-2029
6.7.2 Turkey Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.7.3 Israel Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.7.4 Saudi Arabia Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
6.7.5 UAE Gene-based Advanced Therapy Medicinal Market Size, 2018-2029
7 Gene-based Advanced Therapy Medicinal Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Gene-based Advanced Therapy Medicinal Major Product Offerings
7.1.4 Biogen Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Gene-based Advanced Therapy Medicinal Major Product Offerings
7.2.4 Novartis Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Company Summary
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Gene-based Advanced Therapy Medicinal Major Product Offerings
7.3.4 Gilead Sciences Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.3.5 Gilead Sciences Key News & Latest Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Company Summary
7.4.2 Sarepta Therapeutics Business Overview
7.4.3 Sarepta Therapeutics Gene-based Advanced Therapy Medicinal Major Product Offerings
7.4.4 Sarepta Therapeutics Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.4.5 Sarepta Therapeutics Key News & Latest Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Company Summary
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medicinal Major Product Offerings
7.5.4 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.5.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Gene-based Advanced Therapy Medicinal Major Product Offerings
7.6.4 Amgen Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Company Summary
7.7.2 Spark Therapeutics Business Overview
7.7.3 Spark Therapeutics Gene-based Advanced Therapy Medicinal Major Product Offerings
7.7.4 Spark Therapeutics Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.7.5 Spark Therapeutics Key News & Latest Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Company Summary
7.8.2 Akcea Therapeutics Business Overview
7.8.3 Akcea Therapeutics Gene-based Advanced Therapy Medicinal Major Product Offerings
7.8.4 Akcea Therapeutics Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.8.5 Akcea Therapeutics Key News & Latest Developments
7.9 Sunway Biotech
7.9.1 Sunway Biotech Company Summary
7.9.2 Sunway Biotech Business Overview
7.9.3 Sunway Biotech Gene-based Advanced Therapy Medicinal Major Product Offerings
7.9.4 Sunway Biotech Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.9.5 Sunway Biotech Key News & Latest Developments
7.10 SIBIONO
7.10.1 SIBIONO Company Summary
7.10.2 SIBIONO Business Overview
7.10.3 SIBIONO Gene-based Advanced Therapy Medicinal Major Product Offerings
7.10.4 SIBIONO Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.10.5 SIBIONO Key News & Latest Developments
7.11 AnGes
7.11.1 AnGes Company Summary
7.11.2 AnGes Business Overview
7.11.3 AnGes Gene-based Advanced Therapy Medicinal Major Product Offerings
7.11.4 AnGes Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.11.5 AnGes Key News & Latest Developments
7.12 Orchard Therapeutics
7.12.1 Orchard Therapeutics Company Summary
7.12.2 Orchard Therapeutics Business Overview
7.12.3 Orchard Therapeutics Gene-based Advanced Therapy Medicinal Major Product Offerings
7.12.4 Orchard Therapeutics Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.12.5 Orchard Therapeutics Key News & Latest Developments
7.13 Human Stem Cells Institute
7.13.1 Human Stem Cells Institute Company Summary
7.13.2 Human Stem Cells Institute Business Overview
7.13.3 Human Stem Cells Institute Gene-based Advanced Therapy Medicinal Major Product Offerings
7.13.4 Human Stem Cells Institute Gene-based Advanced Therapy Medicinal Revenue in Global Market (2018-2023)
7.13.5 Human Stem Cells Institute Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の遺伝子ベース先端治療医療市場予測2023-2029：ウイルス遺伝子送達システム、非ウイルス遺伝子送達システム |
| 【英語タイトル】Gene-based Advanced Therapy Medicinal Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5584 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：66 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の遺伝子ベース先端治療医療市場規模と予測を収録しています。・世界の遺伝子ベース先端治療医療市場：売上、2018年-2023年、2024年-2029年 ・世界の遺伝子ベース先端治療医療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の遺伝子ベース先端治療医療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ウイルス遺伝子送達システム」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 遺伝子ベース先端治療医療のグローバル主要企業は、Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Instituteなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、遺伝子ベース先端治療医療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の遺伝子ベース先端治療医療市場：タイプ別、2018年-2023年、2024年-2029年 世界の遺伝子ベース先端治療医療市場：タイプ別市場シェア、2022年 ・ウイルス遺伝子送達システム、非ウイルス遺伝子送達システム 世界の遺伝子ベース先端治療医療市場：用途別、2018年-2023年、2024年-2029年 世界の遺伝子ベース先端治療医療市場：用途別市場シェア、2022年 ・神経疾患、がん、その他 世界の遺伝子ベース先端治療医療市場：地域・国別、2018年-2023年、2024年-2029年 世界の遺伝子ベース先端治療医療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における遺伝子ベース先端治療医療のグローバル売上、2018年-2023年 ・主要企業における遺伝子ベース先端治療医療のグローバル売上シェア、2022年 ・主要企業における遺伝子ベース先端治療医療のグローバル販売量、2018年-2023年 ・主要企業における遺伝子ベース先端治療医療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Institute ************************************************************* ・調査・分析レポートの概要 遺伝子ベース先端治療医療市場の定義 市場セグメント 世界の遺伝子ベース先端治療医療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の遺伝子ベース先端治療医療市場規模 世界の遺伝子ベース先端治療医療市場規模：2022年 VS 2029年 世界の遺伝子ベース先端治療医療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの遺伝子ベース先端治療医療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の遺伝子ベース先端治療医療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ウイルス遺伝子送達システム、非ウイルス遺伝子送達システム 遺伝子ベース先端治療医療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：神経疾患、がん、その他 遺伝子ベース先端治療医療の用途別グローバル売上・予測 ・地域別市場分析 地域別遺伝子ベース先端治療医療市場規模 2022年と2029年 地域別遺伝子ベース先端治療医療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Institute ... |
Gene Delivery System or Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery.
This report aims to provide a comprehensive presentation of the global market for Gene-based Advanced Therapy Medicinal, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene-based Advanced Therapy Medicinal. This report contains market size and forecasts of Gene-based Advanced Therapy Medicinal in global, including the following market information:
Global Gene-based Advanced Therapy Medicinal Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene-based Advanced Therapy Medicinal market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Viral Gene Delivery System Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Gene-based Advanced Therapy Medicinal include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics and Sunway Biotech, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene-based Advanced Therapy Medicinal companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene-based Advanced Therapy Medicinal Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene-based Advanced Therapy Medicinal Market Segment Percentages, by Type, 2022 (%)
Viral Gene Delivery System
Non-viral Gene Delivery System
Global Gene-based Advanced Therapy Medicinal Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene-based Advanced Therapy Medicinal Market Segment Percentages, by Application, 2022 (%)
Neurological Diseases
Cancer
Other
Global Gene-based Advanced Therapy Medicinal Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene-based Advanced Therapy Medicinal Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene-based Advanced Therapy Medicinal revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene-based Advanced Therapy Medicinal revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene-based Advanced Therapy Medicinal, market overview.
Chapter 2: Global Gene-based Advanced Therapy Medicinal market size in revenue.
Chapter 3: Detailed analysis of Gene-based Advanced Therapy Medicinal company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene-based Advanced Therapy Medicinal in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の遺伝子ベース先端治療医療市場予測2023-2029：ウイルス遺伝子送達システム、非ウイルス遺伝子送達システム] (コード：MMG23JU5584)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の遺伝子ベース先端治療医療市場予測2023-2029：ウイルス遺伝子送達システム、非ウイルス遺伝子送達システム]についてメールでお問い合わせ |
